Evidence map›Paper›PMID 37168662›Full record

ArticleJVS-vascular science2023

Mechanisms and efficacy of metformin-mediated suppression of established experimental abdominal aortic aneurysms.

Baohui Xu, Gang Li, Yankui Li, Hongping Deng, Anna Cabot, Jia Guo, Makoto Samura, Xiaoya Zheng, Tiffany Chen, Sihai Zhao and 2 more

Open access · goldAbstract read
In one paragraph

Article in JVS-vascular science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Baohui XuDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Gang LiDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Yankui LiDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Hongping DengDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Anna CabotDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Jia GuoDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Makoto SamuraDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Xiaoya ZhengDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Tiffany ChenDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Sihai ZhaoDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Naoki FujimuraDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Ronald L DalmanDepartment of Surgery, Stanford University School of Medicine, Stanford, CA.
Stanford University · USShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Metformin treatment attenuates experimental abdominal aortic aneurysm (AAA) formation, as well as reduces clinical AAA diameter enlargement in patients with diabetes. The mechanisms of metformin-mediated aneurysm suppression, and its efficacy in suppressing established experimental aneurysms, remain uncertain. Methods: Experimental AAAs were created in male C57BL/6J mice via intra-aortic infusion of porcine pancreatic elastase. Metformin alone (250 mg/kg), or metformin combined with the 5' AMP-activated protein kinase (AMPK) antagonist Compound C (10 mg/kg), were administered to respective mouse cohorts daily beginning 4 days following AAA induction. Further AAA cohorts received either the AMPK agonist AICA riboside (500 mg/kg) as positive, or vehicle (saline) as negative, controls. AAA progression in all groups was assessed via serial in vivo ultrasonography and histopathology at sacrifice. Cytokine-producing T cells and myeloid cellularity were determined by flow cytometric analyses. Results: Metformin limited established experimental AAA progression at 3 (-85%) and 10 (-68%) days following treatment initiation compared with saline control. Concurrent Compound C treatment reduced this effect by approximately 50%. In metformin-treated mice, reduced AAA progression was associated with relative elastin preservation, smooth muscle cell preservation, and reduced mural leukocyte infiltration and neoangiogenesis compared with vehicle control group. Metformin also resulted in reduced interferon-γ-, but not interleukin-10 or -17, producing splenic T cells in aneurysmal mice. Additionally, metformin therapy increased circulating and splenic inflammatory monocytes (CD11b Conclusions: Metformin treatment suppresses existing experimental AAA progression in part via AMPK agonist activity, limiting interferon-γ-producing T cell differentiation while enhancing circulating and splenic inflammatory monocyte retention.

Indexed as

5′ AMP-activated protein kinaseAbdominal aortic aneurysmCytokineInflammatory monocytesMetformin

Identifiers

PMID37168662
PMCPMC10165270
OpenAlexW4362466459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.